Expansion Potential PharmaLogic is rapidly expanding its radiopharmaceutical manufacturing footprint across the United States and internationally, signaling strong capacity growth and potential for expanded CDMO services, co-development partnerships, and overfill opportunities with Ratio Therapeutics and other radiopharma clients.

Therapeutic Leadership The company is the world’s only cGMP-compliant CDMO currently manufacturing and distributing a commercial radiopharmaceutical therapeutic in over 30 countries, presenting a unique pitch to oncologic and radiopharmacy customers seeking compliant, scalable manufacturing and global distribution.

Strategic Partnerships Recent collaborations with Ratio Therapeutics and a broad network of more than 45 facilities create a compelling case for multi-site manufacturing, late-stage development support, and global distribution services for partners advancing radiopharmaceuticals.

Diagnostics Growth The expanding diagnostics business in oncology, cardiology, and Alzheimer's disease opens up cross-sell opportunities for imaging agents, companion diagnostics, and service bundles that combine development, manufacturing, and regulatory support.

Capex Readiness Announcements of major facility openings and a $250M investment signal a willingness to undertake high-capex collaborations with sponsors needing scale-up, site-specific manufacturing capacity, and accelerated time-to-market for radiopharmaceutical products.